Multiple Myeloma (Plasma Cell Neoplasm) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Multiple myeloma is a malignancy of terminally differentiated B-lymphocytes — clonal plasma cells — characterised by uncontrolled proliferation within the bone marrow, production of a monoclonal immunoglobulin paraprotein (M-protein) detectable in serum or urine, and end-organ damage mediated by tumour mass effect, osteoclast activation, and immune suppression. It is the second most common haematological malignancy globally, with approximately 176,000 new cases per year worldwide and a global prevalence rising rapidly as survival improves.

Myeloma exists on a biological continuum. The precursor states — Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smouldering Multiple Myeloma (SMM) — progress to symptomatic myeloma at rates of approximately 1% per year and 10% per year respectively, underscoring the importance of surveillance protocols. The International Myeloma Working Group (IMWG) 2014 diagnostic criteria, updated and refined in 2016, revolutionised the diagnostic threshold by incorporating biomarkers of myeloma-defining events (SLiM criteria) that mandate treatment even before CRAB organ damage develops, enabling earlier therapeutic intervention in patients at imminent risk of rapid progression.

The therapeutic landscape for myeloma has been transformed over the past two decades. The introduction of immunomodulatory agents (IMiDs) — thalidomide, lenalidomide, pomalidomide — and proteasome inhibitors (PIs) — bortezomib, carfilzomib, ixazomib — produced rapid improvement in response rates and survival. The subsequent advent of anti-CD38 monoclonal antibodies (daratumumab, isatuximab) as frontline agents, and most recently B-cell maturation antigen (BCMA)-targeted CAR-T cell therapies (ciltacabtagene autoleucel, idecabtagene vicleucel), has produced a paradigm shift toward achieving minimal residual disease (MRD) negativity as the primary therapeutic benchmark and has made long-term disease-free survival a realistic goal in younger patients.

Multiple myeloma and related plasma cell dyscrasias produce a distinctive constellation of end-organ manifestations managed by the haematology team:

CRAB Criteria — Classic Myeloma End-Organ Damage:

• C — hyperCalcaemia: Serum calcium >0.25 mmol/L above upper normal limit, or >2.75 mmol/L. Caused by osteoclast activation via RANKL overexpression. Presents as polyuria, polydipsia, constipation, confusion, and cardiac arrhythmia. Medical emergency when calcium exceeds 3.5 mmol/L.
• R — Renal impairment: Creatinine clearance <40 ml/min or serum creatinine >177 micromol/L. Cast nephropathy (myeloma kidney) is the most common mechanism — free light chains precipitate with Tamm-Horsfall protein in tubules. Accounts for 20% of myeloma diagnoses presenting as acute kidney injury.
• A — Anaemia: Normocytic normochromic anaemia with haemoglobin >20 g/L below lower normal limit, or haemoglobin <100 g/L. Caused by marrow replacement, erythropoietin deficiency, and inflammatory cytokine inhibition of erythropoiesis.
• B — Bone lesions: Lytic skeletal lesions, severe osteoporosis, or pathological fractures on CT/PET-CT or whole-body low-dose CT. Vertebral compression fractures cause severe back pain and spinal cord compression. Bisphosphonate therapy (zoledronic acid) or denosumab are standard for skeletal protection.

SLiM-CRAB Biomarkers (2014 IMWG addition): Bone marrow plasma cells >60%; serum involved-to-uninvolved free light chain ratio >100; more than one focal lesion on MRI — each independently mandates treatment initiation even without classic CRAB features.

Treatment eligibility for multiple myeloma is stratified primarily by transplant eligibility and cytogenetic risk, as these two factors determine both the intensity of induction therapy and the long-term treatment goals:

Transplant-Eligible Patients (typically age <70–75 years, adequate performance status, no significant comorbidity):

• Fit patients who can tolerate high-dose melphalan (200 mg/m2) conditioning and autologous stem cell transplantation (ASCT) are offered the most intensive and potentially curative-intent treatment pathway.
• The PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) and IFM (Intergroupe Francophone du Myélome) trials established autologous SCT as superior to conventional chemotherapy in eligible patients, with landmark results confirming improved EFS and OS, and form the basis of all current transplant-eligible treatment algorithms.

Transplant-Ineligible Patients (age >75, frailty, organ dysfunction, patient preference):

• Continuous lenalidomide-dexamethasone (Rd) or daratumumab-lenalidomide-dexamethasone (MAIA trial: D-Rd) are the preferred frontline regimens for non-transplant-eligible patients, with MAIA demonstrating median progression-free survival of 61.9 months versus 34.4 months for Rd alone (Facon et al., NEJM 2019).

Cytogenetic risk stratification by FISH panel (del 17p, t(4;14), t(14;16), t(14;20), 1q21 amplification) determines high-risk versus standard-risk disease and guides induction regimen selection and maintenance duration. R-ISS (Revised International Staging System) incorporating LDH, FISH, and beta-2 microglobulin provides the prognostic framework for clinical decision-making and trial stratification. High-risk cytogenetics generally warrants PI-containing maintenance therapy and early consideration of clinical trial enrolment.

Multiple myeloma treatment follows a sequenced strategy of induction, consolidation, and maintenance, with treatment selection guided by transplant eligibility, cytogenetic risk, and prior lines of therapy:

Frontline Induction — Transplant-Eligible Patients:

• Daratumumab-VRd (Dara-VRd): The GRIFFIN trial (Voorhees et al., Blood 2020) demonstrated that adding daratumumab to VRd (bortezomib-lenalidomide-dexamethasone) significantly improved stringent complete response and MRD negativity rates compared to VRd alone, establishing Dara-VRd as the new standard of care frontline induction for transplant-eligible patients in the USA and increasingly in Europe.
• VRd (Bortezomib-Lenalidomide-Dexamethasone): The SWOG S0777 trial established VRd as superior to Rd alone, and it remains widely used in centres where daratumumab approval for frontline use is pending or access is limited.

Consolidation — Autologous Stem Cell Transplantation (ASCT): Peripheral blood stem cell mobilisation (G-CSF ± plerixafor) followed by high-dose melphalan (HDM 200 mg/m2) conditioning and ASCT deepens response and prolongs PFS. Tandem ASCT improves outcomes in high-risk cytogenetic subgroups per EMN02/HO95 trial data.

Maintenance Therapy: Lenalidomide maintenance post-ASCT (CALGB 100104, IFM 2005-02 trials) prolongs PFS by 3–4 years compared to placebo. Bortezomib maintenance is preferred for high-risk cytogenetics including del 17p.

Relapsed/Refractory Myeloma (RRMM):

• Carfilzomib-Lenalidomide-Dexamethasone (KRd): The ENDURANCE trial compared KRd with VRd in newly diagnosed patients; in RRMM, carfilzomib-based regimens produce high response rates in lenalidomide-refractory disease.
• Isatuximab (anti-CD38 mAb): ICARIA-MM and IKEMA trials established isatuximab-pomalidomide-dexamethasone and isatuximab-carfilzomib-dexamethasone as active regimens in RRMM.
• CAR-T Cell Therapy: Idecabtagene vicleucel (ide-cel; KarMMa trial) and ciltacabtagene autoleucel (cilta-cel; CARTITUDE-1 trial) — both BCMA-targeted CAR-T products — demonstrate overall response rates of 73–98% and deep MRD-negative responses in triple-class-refractory myeloma. Cilta-cel shows particularly durable responses with estimated 2-year PFS of 61% in CARTITUDE-1.

The transformation of multiple myeloma from a rapidly fatal disease to a chronic manageable condition with improving long-term survival represents one of the most dramatic success stories in modern oncology:

• Overall survival improvement: Median overall survival has improved from approximately 3 years in the pre-novel-agent era (pre-2000) to over 8–10 years in clinical trial populations receiving modern triplet induction plus ASCT plus maintenance. 10-year overall survival approaching 40% has been documented in younger transplant-eligible patients in population-based registry studies from Sweden, the Netherlands, and Denmark.
• MRD negativity as a therapeutic benchmark: Achievement of MRD negativity (defined as fewer than 1 myeloma cell per 100,000 normal bone marrow cells, assessed by next-generation flow cytometry or next-generation sequencing) is the strongest independent predictor of PFS and OS, regardless of treatment regimen. Daratumumab-based induction achieves MRD negativity rates of 60–75% by the end of induction, compared with 25–35% with VRd alone.
• Functional recovery: Modern treatment produces rapid resolution of CRAB features. Renal impairment recovers in 60–70% of patients with treatment; anaemia corrects in the majority within 2–4 cycles; hypercalcaemia responds within days to bisphosphonate therapy combined with antimyeloma treatment.
• ASCT consolidation benefit: A landmark meta-analysis of 15 randomised trials confirmed that ASCT extends PFS by a median of 12 months compared to conventional chemotherapy consolidation alone in transplant-eligible patients, even in the novel-agent era.
• CAR-T efficacy in refractory disease: Cilta-cel (CARTITUDE-1) achieved a 98% overall response rate and 78% very good partial response or better in heavily pre-treated triple-class-refractory patients, with 4-year follow-up demonstrating durable remissions in a substantial proportion of responders — a level of efficacy previously unimaginable in this population.

Multiple myeloma treatment carries significant toxicities that require proactive monitoring and multidisciplinary supportive care:

• Peripheral neuropathy: Bortezomib-related peripheral neuropathy (painful, predominantly sensory) occurs in up to 30–40% of patients with intravenous administration but is substantially reduced (<10% Grade 3+) with subcutaneous dosing (SQ bortezomib is now standard). Lenalidomide causes milder peripheral neuropathy; carfilzomib has a more favourable neuropathy profile than bortezomib.
• Venous thromboembolism (VTE): IMiD-based regimens (lenalidomide, pomalidomide) carry significant VTE risk — up to 15–25% without thromboprophylaxis. All patients on IMiD-containing regimens require systematic thromboprophylaxis: aspirin for low-risk patients, low-molecular-weight heparin or direct oral anticoagulants (DOACs) for high-risk patients. IMWG VTE risk assessment tools guide prophylaxis selection.
• Infection and immunosuppression: Myeloma itself causes humoral immunodeficiency (hypogammaglobulinaemia); treatment compounds this with additional immunosuppression. Pneumocystis jirovecii pneumonia (PJP) prophylaxis (co-trimoxazole) and antiviral herpes prophylaxis (aciclovir) are mandatory during bortezomib therapy. Intravenous immunoglobulin (IVIG) replacement is used for recurrent severe infections. Anti-CD38 antibodies cause transfusion reaction interference (false-positive indirect antiglobulin test) requiring specialist blood bank protocols.
• Daratumumab infusion reactions: Occur in 40–50% of patients at first infusion, predominantly during the first hour. Managed with pre-medication (corticosteroid, antihistamine, antipyretic), infusion rate reduction, and temporary interruption. Grade 3–4 infusion reactions occur in fewer than 5% of patients.
• CAR-T specific toxicities: Cytokine release syndrome (CRS) — fever, hypotension, hypoxia — occurs in 80–95% of patients receiving BCMA-directed CAR-T, with Grade 3+ CRS in 5–10%. Immune effector cell-associated neurotoxicity syndrome (ICANS) occurs in 20–30% of patients. Both are managed with tocilizumab, corticosteroids, and intensive supportive care in CAR-T-experienced specialist centres. Movement and neurocognitive adverse effects (CAPA syndrome) are a specific concern with cilta-cel requiring neurological monitoring.

Multiple myeloma is a chronic relapsing condition requiring lifelong surveillance. Modern follow-up protocols incorporate both conventional response assessment and MRD monitoring:

• Haematological response assessment: M-protein quantification by serum protein electrophoresis (SPEP) and serum free light chains (SFLC) is performed every 1–3 months during active treatment and every 3 months during maintenance. Response categories (sCR, CR, VGPR, PR, SD, PD) follow IMWG uniform response criteria (Kumar et al., 2016), enabling standardised monitoring across treatment centres internationally.
• MRD monitoring: Next-generation flow cytometry (EuroFlow 8-colour panel, minimum 5 × 10^6 cells analysed) or next-generation sequencing (NGS-based clonoSEQ assay, sensitivity 10^-6) is performed on bone marrow aspirates at response assessment milestones — post-induction, post-ASCT, 12 and 24 months on maintenance. Sustained MRD negativity (>12 months) is increasingly used to guide maintenance cessation decisions in clinical trials.
• Imaging surveillance: Whole-body low-dose CT (WBLDCT) or PET-CT annually during maintenance and at suspected relapse. PET-CT is the preferred modality for MRD-driven imaging, as it detects extramedullary disease and residual metabolically active focal lesions not captured by bone marrow MRD assessment alone.
• Bone health monitoring: Annual DXA scan; continuation of zoledronic acid (4 mg IV monthly for 12–24 months, then every 3 months) or denosumab (120 mg SC monthly) throughout active treatment. Osteonecrosis of the jaw (ONJ) monitoring with annual dental review and avoidance of invasive dental procedures during bisphosphonate therapy.
• Endocrinological and quality of life assessment: Annual assessment of fatigue, cognitive function, peripheral neuropathy grading, sexual health (in patients on androgen-depressing corticosteroid regimens), and quality of life using EORTC QLQ-MY20 or FACT-MM instruments to guide supportive care and psychosocial intervention.

Multiple myeloma is one of the most cost-intensive cancers to treat, reflecting the duration of therapy, expense of novel agents, and complexity of transplantation. Key cost dimensions include:

• Novel agent costs: Lenalidomide (until biosimilar entry) cost approximately USD 20,000–30,000 per month in the USA; daratumumab (subcutaneous formulation) costs approximately USD 6,000–10,000 per infusion cycle. A full frontline Dara-VRd induction course (6 cycles) can exceed USD 200,000 in the USA. NHS England negotiates conditional access agreements and cost-effectiveness thresholds (typically <£30,000 per QALY) for novel agent reimbursement, significantly reducing patient-facing costs to zero under the NHS.
• Autologous SCT costs: A single ASCT in the UK (NHS) is provided without charge at designated transplant centres. Private ASCT in the UK costs approximately £40,000–60,000. In India (Tata Memorial, Apollo, Manipal), total ASCT costs range USD 15,000–30,000 including hospitalisation and supportive care, representing 70–80% cost savings versus the USA. Medical tourism for ASCT in India or Turkey attracts significant international patient volumes.
• CAR-T therapy costs: Commercially approved BCMA-directed CAR-T products (ide-cel, cilta-cel) are priced at USD 465,000–480,000 per infusion in the USA. NHS England has negotiated access to cilta-cel for relapsed/refractory myeloma at confidential commercial terms. CAR-T manufacturing infrastructure constraints limit global access; cell therapy programmes in India, South Korea, and China are developing autologous BCMA CAR-T products at significantly lower cost.
• Biosimilars impact: Lenalidomide biosimilars received EMA and FDA approval in 2022, reducing acquisition costs by 40–60% and substantially improving access in middle-income countries. Bortezomib biosimilars have been available since 2016 and are widely used globally. Biosimilar daratumumab development is ongoing.
• Medical tourism: Patients from high-income countries considering myeloma treatment at accredited haematology centres in India (Tata Memorial Hospital Mumbai, Apollo Hospitals, Manipal) or Singapore can access equivalent triplet induction regimens, ASCT, and post-transplant maintenance at 50–75% lower total cost than equivalent private-sector care in the UK, USA, or Australia.

The myeloma therapeutic landscape is among the most rapidly evolving in oncology. Beyond current standard approaches, the following alternative and emerging strategies are clinically relevant:

• Allogeneic stem cell transplantation (allo-SCT): Potentially curative via graft-versus-myeloma effect but associated with significant treatment-related mortality (15–25%). Reserved for young, fit patients with high-risk disease refractory to multiple lines of therapy, ideally within a clinical trial at experienced transplant centres. The myeloma community remains divided on the role of allo-SCT given competing efficacy of CAR-T and bispecific antibody therapies.
• Bispecific T-cell engager antibodies: Teclistamab (BCMA x CD3; MajesTEC-1 trial), talquetamab (GPRC5D x CD3; MonumenTAL-1 trial), and elranatamab (BCMA x CD3) achieve overall response rates of 60–70% in triple-class-refractory myeloma as off-the-shelf, immediately available alternatives to CAR-T therapy, without the 4–8 week manufacturing delay and logistical complexity of autologous cell therapy. Both teclistamab and talquetamab received FDA approval in 2023.
• Venetoclax for t(11;14) myeloma: Venetoclax (BCL-2 inhibitor) demonstrates selective activity in the 15–20% of myeloma patients harbouring t(11;14) translocations, which confer high BCL-2 expression. BELLINI trial data support venetoclax-bortezomib-dexamethasone in this molecularly defined subgroup, making cytogenetic testing essential for treatment selection.
• Cereblon E3 ligase modulator degraders (CELMoDs): Next-generation IMiDs — iberdomide (CC-220) and mezigdomide (CC-92480) — demonstrate activity in lenalidomide- and pomalidomide-refractory disease through enhanced IKZF1/3 degradation and are in Phase III trials for RRMM.
• Observation for high-risk SMM: ECOG E3A06 and QUIREDEX trials demonstrated that early treatment of high-risk smouldering myeloma (HRSMM) with lenalidomide delays progression to symptomatic myeloma and improves overall survival, establishing early intervention as an emerging standard in HRSMM management and an alternative to watchful waiting in selected patients.